Crossmark

Adjuvant chemotherapy after severe myelotoxicity during chemoradiation phase in malignant gliomas. Is it feasibile? Results from AINO study (Italian Association for Neuro-Oncology)

Crossref DOI link: https://doi.org/10.1007/s00415-021-10438-4

Published Online: 2021-02-20

Published Print: 2021-08

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Villani, Veronica http://orcid.org/0000-0001-8769-9966
Anghileri, Elena

Prosperini, Luca

Lombardi, Giuseppe

Rudà, Roberta

Gaviani, Paola

Rizzato, Simona

Lanzetta, Gaetano

Fabi, Alessandra

Scaringi, Claudia

Pronello, Edoardo

Simonetti, Giorgia

Targato, Giada

Pace, Andrea
License Information

Text and Data Mining valid from 2021-02-20

Version of Record valid from 2021-02-20
More Information

Article History

Received: 16 December 2020

Revised: 29 January 2021

Accepted: 30 January 2021

First Online: 20 February 2021

Compliance with ethical standards

:

: The author declares that they have no conflict of interest.

: Informed consent, in line with the principles of the Declaration of Helsinki, was obtained from all individual participants included in the study.

Document is current

Any future updates will be listed below